Placebo (0.9% NaCl)

OTHER5 trials

Sponsors

University Hospital Dubrava, University Hospital, Basel, Switzerland, Talphera, Inc, Sanofi

Conditions

Acute Kidney InjuryCOVID-19 ImmunizationColorectal CancerInfluenza ImmunizationPostprandial Hypoglycemia

Phase 1

Study of a Combination Vaccine Comprised of Different Recombinant Spike Antigen Levels of a Matrix-M Adjuvanted Recombinant COVID-19 Vaccine and Recombinant Influenza Vaccine in Adult Participants 50 Years of Age and Older

Active, not recruitingNCT06695130

SanofiCOVID-19 Immunization, Influenza Immunization

Start: 2024-11-18End: 2026-04-03Updated: 2025-05-28

Study of a Combination Vaccine Comprised of Different Recombinant Spike Antigen Levels of a Matrix-M Adjuvanted Recombinant COVID-19 Vaccine and High-Dose Inactivated Influenza Vaccine in Adult Participants 50 Years of Age and Older

Active, not recruitingNCT06695117

SanofiCOVID-19 Immunization, Influenza Immunization

Start: 2024-11-19End: 2026-04-01Updated: 2025-04-01

Phase 3

Canakinumab for the Treatment of Postprandial Hypoglycemia

RecruitingNCT05401578

University Hospital, Basel, SwitzerlandPostprandial Hypoglycemia

Start: 2023-04-17End: 2026-05-31Target: 56Updated: 2025-01-29

Unknown Phase

The Anti-inflammatory Effect of Anesthetics in Abdominal Surgery

CompletedNCT03821545

University Hospital DubravaColorectal Cancer

Start: 2019-01-28End: 2021-06-18Updated: 2022-05-20

Nafamostat Efficacy in Phase 3 Registrational CRRT Study

RecruitingNCT06150742

Talphera, IncAcute Kidney Injury

Start: 2024-08-15End: 2025-12-31Target: 70Updated: 2025-10-15

Related Papers

Canakinumab for the treatment of postprandial hypoglycaemia: study protocol for a randomised, placebo-controlled, parallel-group, double-blind, multicentric, superiority trial—the CanpHy study

BMJ Open2025-05-01